search
Rufe wannan akwatin nema.

Ma'aikatan Lafiya

Sabuntawa na PBAC

PBAC wata ƙungiyar ƙwararrun ƙwararru ce mai zaman kanta wacce Gwamnatin Ostiraliya ta naɗa. Membobin sun haɗa da likitoci, ƙwararrun kiwon lafiya, masana tattalin arziki na kiwon lafiya da wakilan mabukaci.

Matsayinsu shine ba da shawarar sabbin magunguna don jeri akan tsarin fa'idodin magunguna (PBS). Ba za a iya lissafa sabon magani ba sai dai idan kwamitin ya ba da shawara mai kyau. PBAC na saduwa sau uku a shekara, yawanci Maris, Yuli da Nuwamba.

A kan wannan shafi:

Ajandar taron PBAC mai zuwa:

Nuwamba 2020

Lymphoma da CLL ƙaddamarwa a cikin ajanda mai zuwa

Nuwamba 2020 ƙaddamarwar lymphoma/CLL akan ajanda

Nau'in ƙaddamarwa Sunan magani da mai tallafawa Nau'in miyagun ƙwayoyi da amfani Jerin da aka nema ta masu tallafawa & manufa
Sabon jeri (ƙaramin sallama) Ibrutinib Cutar sankarar lymphocytic na yau da kullun (CLL); Ƙananan lymphoma lymphocytic (SLL); Mantle cell lymphoma Don neman izini Lissafin da ake buƙata na kwamfutar hannu ibrutinib a ƙarƙashin sharuɗɗa iri ɗaya kamar na capsule da aka riga aka jera.
Sabon jeri  (ƙaramin sallama) Mogamulizumab (Kyowa Kirin) Cutaneous T-cell lymphoma (CTCL) Sake ƙaddamarwa don buƙatar Sashe na 100 (ingantaccen kuɗaɗen chemotherapy) Hukumar da ake buƙatar jeri don marasa lafiya tare da CTCL da suka koma baya ko kuma waɗanda aka yi musu magani a baya tare da aƙalla magani na gaba ɗaya.

Sakamakon taron PBAC

Yuli 2020

Lymphoma da CLL ƙaddamarwa & sakamako

Sakamakon taron PBAC na Yuli 2020 don ƙaddamar da lymphoma da CLL

Drug, mai tallafawa, nau'in ƙaddamarwaNau'in magani ko amfaniLissafin da aka nema ta hanyar mai tallafawa/maƙasudin ƙaddamarwaSakamakon PMAC

Hakanan 

(AbbVie)

Canja zuwa jeri (ƙaramin ƙaddamarwa)

Ciwon sankarar sankarar bargo na zamani (CLL)Sake ƙaddamarwa don neman jeri da ake buƙata na Hukuma, tare da Obinutuzumab, don jiyya na farko na marasa lafiya tare da CLL waɗanda ke da yanayin rayuwa tare don maganin cutar sankara na fludarabine.PBAC ta ba da shawarar jeri na venetoclax a haɗe tare da obinutuzumab don jiyya na farko na marasa lafiya tare da CLL waɗanda ke da yanayi tare kuma basu dace da maganin rigakafi na fludarabine ba. 
Acalabrutinib (AstraZeneca)Cutar sankarar jini na yau da kullun (CLL) ko ƙananan lymphoma lymphocytic (SLL)Don neman jerin sunayen da ake buƙata na Hukuma don kula da marasa lafiya (ko dai a matsayin monotherapy ko a haɗe tare da obinutuzumab) tare da CLL ko SLL da ba a kula da su a baya ba wanda aka ɗauka bai dace da magani tare da analog na purine ba. Buƙatun na biyu shine don amfani kawai a cikin rukunin marasa lafiya tare da gogewar 17p. 

PBAC ba ta yi ba bayar da shawarar jeri na acalabrutinib, don amfani azaman monotherapy ko a hade tare da obinutuzumab, don jiyya na farko na marasa lafiya tare da CLL ko SLL waɗanda aka ɗauka basu dace da jiyya tare da analog na purine ba. PBAC ta yi la'akari da cewa haɓakar haɓakar ƙimar ƙimar ya kasance mai girma mara yarda da rashin tabbas a farashin da aka tsara. 

Mogamulizumab

(Kyowa Kirin)

Cutaneous T-cell lymphoma (CTCL)Don neman sashe na 100 (Ingantacciyar Kuɗi na Chemotherapy) Hukumar da ake buƙata (Rubuta) ga marasa lafiya tare da CTCL da suka koma baya ko waɗanda aka yi musu magani a baya tare da aƙalla magani na gaba ɗaya. PBAC ba ta ba da shawarar jeri na mogamulizumab don kula da marasa lafiya tare da CTCL da suka koma baya ba ko kuma sun bi bayan aƙalla jiyya na tsarin gaba ɗaya don wannan yanayin. PBAC ta yi la'akari da cewa girman fa'ida ga mogamulizumab dangane da ci gaban rayuwa kyauta da rayuwa gabaɗaya ba ta da tabbas. Bugu da ƙari, PBAC ta yi la'akari da ƙimar ƙimar ƙimar haɓakar haɓakar ƙima ba ta da girma kuma ba ta da tabbas a farashin da aka tsara, kuma kiyasin tasirin kuɗi ba shi da tabbas. 

Maris 2020 PBAC taron ajanda don lymphoma/CLL & ficen jiran aiki daga Nuwamba 2019

Sunan magani da mai tallafawa Karamin rubutu An nemi jeri da manufa Rahoton da aka ƙayyade na PBAC
Ibrutinib (Janssen) Cutar sankarar jini na yau da kullun (CLL) ko ƙananan lymphoma lymphocytic (SLL) Sake ƙaddamarwa don neman biyan kuɗin PBS don kula da CLL ko SLL tare da shaidar ɗaya ko fiye da gogewar chromosome 17p. PBAC ya ba da shawarar lissafin PBS na ibrutinib don jiyya na farko tare da CLL/SLL tare da gogewa 17p -har yanzu ana jiran a jera su, tun Nuwamba 2019
Acalabrutinib (AstraZeneca) Cutar sankarar jini na yau da kullun (CLL) ko ƙananan lymphoma lymphocytic (SLL) Don buƙatar lissafin PBS don kula da marasa lafiya tare da sake dawowa ko CLL ko SLL wanda bai dace da magani tare da analog na purine ba. PBAC ya ba da shawarar lissafin acalabrutinib don kula da marasa lafiya tare da R / R CLL / SLL a cikin jiyya na layi na biyu - jiran zama PBS da aka jera tun Maris 2020
Pembrolizumab (MSD) Na farko mediastinal B-cell lymphoma (PMBCL) Sake ƙaddamarwa don buƙatar jeri na PBS don maganin sake dawowa ko rashin ƙarfi na PMCL PBAC ta ba da shawarar lissafin PBS na pembrolizumab don R/R PMBCL - wana neman zama PBS da aka jera tun Maris 2020

Taimako da bayanai

Yi rajista zuwa wasiƙar labarai

Wannan raba
Siyayya

Rajista Labarai

Tuntuɓi Lymphoma Australia A Yau!

Lura: Ma'aikatan Lymphoma Ostiraliya suna iya amsawa kawai ga imel ɗin da aka aika cikin harshen Ingilishi.

Ga mutanen da ke zaune a Ostiraliya, za mu iya ba da sabis na fassarar waya. Ka sa ma'aikacin jinya ko dangin ku masu magana da Ingilishi su kira mu don shirya wannan.